Published in Infect Immun on September 01, 1998
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol (2007) 2.11
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun (1999) 1.80
Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun (2002) 1.15
Molecular cloning and characterization of genes for Shigella sonnei form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector. Infect Immun (2002) 1.03
Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immun (2005) 0.92
Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. Infect Immun (2002) 0.91
Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun (2005) 0.88
Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants. Infect Immun (2009) 0.88
Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine (2009) 0.85
Establishment of a Shigella sonnei human challenge model in Thailand. Vaccine (2012) 0.84
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni. Hum Vaccin Immunother (2015) 0.84
Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta). Comp Med (2008) 0.83
Parameters underlying successful protection with live attenuated mutants in experimental shigellosis. Infect Immun (2001) 0.79
Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults. Clin Vaccine Immunol (2016) 0.76
Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect Immun (1991) 15.39
Selection for loss of tetracycline resistance by Escherichia coli. J Bacteriol (1981) 11.83
Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin. Proc Natl Acad Sci U S A (1989) 7.00
Shigella sonnei plasmids: evidence that a large plasmid is necessary for virulence. Infect Immun (1981) 6.40
[Not Available]. Acta Microbiol Acad Sci Hung (1957) 5.53
Plaque formation by virulent Shigella flexneri. Infect Immun (1985) 4.16
Surface presentation of Shigella flexneri invasion plasmid antigens requires the products of the spa locus. J Bacteriol (1992) 3.91
Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment. Am J Trop Med Hyg (1955) 3.48
Measurement of invasion by gentamicin resistance. Methods Enzymol (1994) 3.38
virG, a plasmid-coded virulence gene of Shigella flexneri: identification of the virG protein and determination of the complete coding sequence. J Bacteriol (1989) 3.31
Diarrheal disease during Operation Desert Shield. N Engl J Med (1991) 3.22
Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines. Bull World Health Organ (1968) 2.68
Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis (1990) 2.52
Epidemiology of common-source outbreaks of shigellosis in the United States, 1961-1975. Am J Epidemiol (1978) 2.30
Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis (1972) 2.29
OmpB (osmo-regulation) and icsA (cell-to-cell spread) mutants of Shigella flexneri: vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine (1991) 1.99
Antimicrobial resistance in organisms causing diarrheal disease. Clin Infect Dis (1997) 1.95
Failure of parenteral vaccines to protect monkeys against experimental shigellosis. Proc Soc Exp Biol Med (1967) 1.46
High frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, streptomycin, chloramphenicol, and tetracycline isolated from patients with shigellosis in northeastern Brazil during the period 1988 to 1993. Antimicrob Agents Chemother (1995) 1.45
Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine (1989) 1.44
Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect Immun (1994) 1.43
Can antibiotic resistance be controlled? N Engl J Med (1994) 1.42
Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect Immun (1992) 1.39
Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect Immun (1991) 1.34
Shigella infections. Ann Trop Med Parasitol (1996) 1.18
Antimicrobial resistance in Shigella flexneri and Shigella sonnei in Hong Kong, 1986 to 1995. Antimicrob Agents Chemother (1998) 1.16
Construction of an auxotrophic Shigella flexneri strain for use as a live vaccine. Microb Pathog (1990) 1.15
Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati). Arch Roum Pathol Exp Microbiol (1986) 1.14
Protection of adult rabbits and monkeys from lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y. Vaccine (1990) 1.14
On the serology of Plesiomonas shigelloides. Jpn J Med Sci Biol (1978) 1.09
Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes. Vaccine (1991) 1.09
Increasing antimicrobial resistance of Shigella isolates in Israel during the period 1984 to 1992. Antimicrob Agents Chemother (1995) 1.02
Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. Infect Immun (1994) 0.98
Construction and characterization of virG (icsA)-deleted Escherichia coli K12-Shigella flexneri hybrid vaccine strains. Vaccine (1996) 0.89
Outpatient studies of the safety and immunogenicity of an auxotrophic Escherichia coli K-12-Shigella flexneri 2a hybrid vaccine candidate, EcSf2a-2. Vaccine (1994) 0.81
Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun (2003) 5.11
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun (1999) 1.80
Human monocyte-derived macrophages infected with virulent Shigella flexneri in vitro undergo a rapid cytolytic event similar to oncosis but not apoptosis. Infect Immun (1997) 1.58
Shigella flexneri IpaH(7.8) facilitates escape of virulent bacteria from the endocytic vacuoles of mouse and human macrophages. Infect Immun (2000) 1.53
Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. Infect Immun (1991) 1.47
Hemolysin-positive enteroaggregative and cell-detaching Escherichia coli strains cause oncosis of human monocyte-derived macrophages and apoptosis of murine J774 cells. Infect Immun (1998) 1.29
Characterization of Shigella type 1 fimbriae: expression, FimA sequence, and phase variation. Infect Immun (1997) 0.97
Spontaneous insertion of an IS1-like element into the virF gene is responsible for avirulence in opaque colonial variants of Shigella flexneri 2a. Infect Immun (1992) 0.93
Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines. Infect Immun (1999) 0.92
Construction and characterization of virG (icsA)-deleted Escherichia coli K12-Shigella flexneri hybrid vaccine strains. Vaccine (1996) 0.89
Evaluation of alkaline phosphatase-labelled ipaH probe for diagnosis of Shigella infections. J Clin Microbiol (1993) 0.87
Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine (2009) 0.85
Molecular epidemiology of Shigella flexneri in a diarrhoea-endemic area of Lima, Peru. Epidemiol Infect (2004) 0.84
Genetic analysis of Shigella sonnei form I antigen: identification of a novel IS630 as an essential element for the form I antigen expression. Microb Pathog (1998) 0.83
Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. Vaccine (2011) 0.82
Inactivation of DsbA alters the behaviour of Shigella flexneri towards murine and human-derived macrophage-like cells. FEMS Microbiol Lett (2001) 0.81
Identification and molecular characterization of a 27 kDa Shigella flexneri invasion plasmid antigen, IpaJ. Microb Pathog (1997) 0.78